Skip to Content

Once-Weekly Insulin Icodec Promising for Type 2 Diabetes

THURSDAY, April 22, 2021 -- Once-weekly insulin icodec is efficacious and well tolerated, according to two phase 2 studies published online April 19 in Diabetes Care.

Ildiko Lingvay, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues randomly assigned 205 insulin-naive adults with type 2 diabetes and hemoglobin A1c 7 to 10 percent while treated with oral glucose-lowering medications to once-weekly icodec titrations A (self-measured blood glucose target 80 to 130 mg/dL; adjustment ±21 units/week), B (80 to 130 mg/dL; ±28 units/week), or C (70 to 108 mg/dL; ±28 units/week) or to once-daily insulin glargine U100 (IGlar U100; 80 to 130 mg/dL; ±4 units/week). The percentage of time in range (TIR; 70 to 180 mg/dL) during weeks 15 and 16 was measured. The researchers found that from baseline to weeks 15 and 16, TIR improved in all groups. Compared with IGlar U100, TIR was greater for titration B (estimated treatment difference, 7.08 percent).

Harpreet S. Bajaj, M.D., M.P.H., from LMC Diabetes and Endocrinology in Brampton, Ontario, Canada, and colleagues conducted a multicenter, open-label trial involving eligible basal insulin-treated individuals with type 2 diabetes who were randomly assigned to icodec with an initial 100 percent loading dose (icodec LD), icodec with no loading dose (icodec NLD), or IGlar U100 for 16 weeks. The researchers found that during weeks 15 to 16, the estimated mean TIR was 72.9, 66.0, and 65.0 percent for icodec LD, icodec NLD, and IGlar U100, respectively, with a significant difference favoring icodec LD versus IGlar U100 (7.9 percent).

"A weekly insulin is a game changer that will decrease the treatment burden for patients while also improving compliance," Lingvay said in a statement.

Several authors from both studies disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Abstract/Full Text - Lingvay (subscription or payment may be required)

Abstract/Full Text - Bajaj (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Risk Factors ID'd for COVID-19-Related Death in Diabetes

MONDAY, May 3, 2021 -- For individuals with diabetes, the risk for COVID-19-related death is increased in association with male sex, older age, preexisting comorbidities, and use...

Younger Age at T2DM Onset Linked to Subsequent Dementia Risk

WEDNESDAY, April 28, 2021 -- Younger age at onset of type 2 diabetes is associated with an increased risk for subsequent dementia, according to a study published in the April 27...

Gender, Race Affects Access to SGLT2-Inhibitor Therapy for T2DM

MONDAY, April 16, 2021 -- There are racial/ethnic, gender, and socioeconomic disparities apparent in access to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment for...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.